Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough
NCT02655562 · Beijing Chao Yang Hospital · PHASE4 · suspended · last registry update 2022-07-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “There are difficulties in recruiting patients” | – | Registry record, Beijing Chao Yang Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYSLTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-06-08Phase 3 first posted: Susanna Naggie, MD, Montelukast (NCT05894577)
- 2023-05-30Results posted on the registry: Sanofi, Isatuximab SAR650984 + Acetaminophen (paracetamol) or equivalent (NCT04294459)
- 2022-09-21Also stopped (suspended): Benha University, dydrgesterone 10 mg( tab)/12hs/14 days + montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days (NCT03794037)
- 2022-06-06Phase 3 first posted: Sanofi, Isatuximab IV + Isatuximab SC (NCT05405166)
- 2022-05-31Results posted on the registry: Boehringer Ingelheim, BI 671800 + Placebo (NCT01103349)
- 2022-05-23Results posted on the registry: ViiV Healthcare, GSK3640254 200 mg + Caffeine 200 mg (NCT04425902)
- 2022-05-05Phase 3 first posted: University of Colorado, Denver, Montelukast (NCT05362474)
- 2022-04-13Phase 3 first posted: Second Xiangya Hospital of Central South University, Nebulized Budesonide + Intranasal Budesonide Spray (NCT05325489)
- 2022-03-24Phase 3 first posted: Ain Shams University, Montelukast Sodium 10 mg + Co-Enzyme Q10 (NCT05293132)
- 2022-02-16Also stopped (withdrawn): Organon and Co, MF/F Metered Dose Inhaler (MDI) 25/5 mcg + MF/F MDI 50/5 mcg (NCT01615874)
- 2022-02-14Also stopped (withdrawn): Organon and Co, Montelukast sodium + Placebo to montelukast (NCT00540839)
- 2022-01-04Results posted on the registry: GlaxoSmithKline, Fluticasone furoate + Placebo (NCT02889809)
- 2021-10-20Also stopped (terminated): Maisonneuve-Rosemont Hospital, Prednisone + Azithromycin (NCT01432080)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision